Batiraxcept clinical trials
Also written AVB-S6-500 and AVB-500.
How each study uses batiraxcept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 4
Aravive, Inc. (6) · Washington University School of Medicine (2) · University of Oklahoma (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Paclitaxel (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses batiraxcept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingPhase 1University of OklahomaNCT04004442Written as AVB-S6-500
- AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04019288Written as Batiraxcept
- AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine CancerWithdrawnPhase 1Washington University School of MedicineNCT05826015Written as Batiraxcept
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminatedPhase 1/2Aravive, Inc.NCT04300140Written as Batiraxcept
- Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerTerminatedPhase 3Aravive, Inc.NCT04729608Written as Batiraxcept
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic AdenocarcinomaTerminatedPhase 1/2Aravive, Inc.NCT04983407Written as batiraxcept
- Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedPhase 1Aravive, Inc.NCT03639246Written as AVB-S6-500
- Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA NephropathyTerminatedPhase 2Aravive, Inc.NCT04042623Written as AVB-S6-500
- Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyWithdrawnPhase 1Washington University School of MedicineNCT03607955Written as AVB-S6-500
- A Phase 1 AVB-S6-500 Safety and Tolerability StudyCompletedPhase 1Aravive, Inc.NCT03401528Written as AVB-S6-500
Codes
What other systems call batiraxcept · ClinicalTrials.gg INT016076
- UNII (FDA) B6840JH4EBBATIRAXCEPTOne source FDA
- NCI Thesaurus C156017BatiraxceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B6840JH4EB | BATIRAXCEPT | One source FDA |
| NCI Thesaurus | C156017 | Batiraxcept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.